Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrated Stress Response (ISR) Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EIF2S1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF2S1 Recombinant Protein (WT, S51A, S51D mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View EIF2S1 Products |
| Gene Delivery | EIF2S1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View EIF2S1 Products |
| Benchmark Ab | Anti-EIF2S1 Recombinant Antibody Recombinant positive control for assay validation. |
View EIF2S1 Products |
| Validator | EIF2S1 siRNA Set For knockdown verification. |
View EIF2S1 Products |
| Related Target A | EIF2AK3 (PERK) Upstream kinase phosphorylating EIF2S1 under endoplasmic reticulum stress. |
View EIF2AK3 Products |
| Related Target B | EIF2B1 Direct downstream effector; phosphorylated EIF2S1 acts as a competitive inhibitor of EIF2B. |
View EIF2B1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphorylation-specific detection (Ser51) | S51A (non-phosphorylatable) and S51D (phosphomimetic) mutant proteins available for absolute specificity validation. |
| Upstream kinase screening (PERK/GCN2/PKR) | High-purity WT EIF2S1 protein strictly verified by mass spectrometry, free from tag interference. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live EIF2S1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The modulation of the Integrated Stress Response (ISR) pathway has emerged as a major therapeutic frontier. EIF2S1 (eIF2α) lies at the absolute crossroads of this pathway. Phosphorylation of EIF2S1 at Ser51 by upstream kinases (such as PERK, GCN2, PKR, and HRI) shuts down global protein synthesis while selectively upregulating stress-adaptive genes like ATF4.
The race for EIF2S1 pathway therapeutics is intensifying, with major players shifting focus from traditional global translation inhibitors to selective ISR modulators. As first-generation upstream kinase inhibitors (e.g., PERK inhibitors) face safety limitations such as pancreatic toxicity, the next wave of R&D is targeting direct protein-protein interactions (such as the eIF2-eIF2B interface) and downstream phosphorylation-mimetic modulation to treat neurodegenerative diseases and refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ISR Activators) | Calico Life Sciences, AbbVie | Neurodegeneration (ALS, Alzheimer's) | In vitro phosphorylation assays (Need sequence-verified WT EIF2S1) |
| Small Molecule (ISR Inhibitors) | Denali Therapeutics, Roche | Cognitive disorders, Vanishing White Matter (VWM) | eIF2-eIF2B binding assays (Need high-purity EIF2S1 and EIF2B complex proteins) |
| Gene Therapy / RNAi | Academic institutions, Biotech startups | Oncology (Refractory solid tumors) | Target knockdown validation (Need verified siRNA sets) |